
Shares of Supernus Pharmaceuticals SUPN.O rise 6.2% to $39.67
SUPN says U.S. FDA has approved its drug-device combination, Onapgo, to treat movement-related symptoms of Parkinson's disease
Approval comes after previous declines in 2022 and 2024 due to quality and device concerns
SUPN says Onapgo will be available in United States in Q2 and is expected to generate $200 mln to 300 mln in peak sales
SUPN gained 30.4% in 2024